Nivolumab, an anti–programmed cell death 1 (PD-1) immuno-oncology (I-O) therapy, is approved and regarded as a standard adjuvant treatment option for patients with completely resected stage III or stage IV melanoma based on findings of the pivotal phase III CheckMate 238 trial [1]. Here, PDCD1 is linked to melanoma.